M&T Bank
CMPX icon

M&T Bank’s Compass Therapeutics CMPX Stock Holding History

M&T Bank’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.6K Buy
15,043
+149
+1% +$860 ﹤0.01% 1647
2025
Q4 		$80K Buy
+14,894
New +$68.8K ﹤0.01% 1636

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

M&T Bank's CMPX Position: Q1 2026 in Review

M&T Bank increased its Compass Therapeutics (CMPX) stake by 1% in Q1 2026, buying an estimated $860 and bringing the position to 15,043 shares worth $79.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

M&T Bank first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $80K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • M&T Bank held 15,043 shares of Compass Therapeutics worth $79.6K as of Q1 2026.
  • M&T Bank bought 149 Compass Therapeutics shares in Q1 2026, an estimated $860.
  • Compass Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #1647 holding.
  • M&T Bank first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • M&T Bank's Compass Therapeutics position peaked at $80K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.